Successful use of anti IL5 targeted therapy (Mepolizumab) in two cases of hypereosinophilic syndrome from India

被引：0
|
作者：
Chopra, Manu [1 ]
Pramanik, Suman [1 ]
Mukherjee, Subhro [1 ]
Chopra, Meenakshi [1 ]
机构：
[1] Indian Army Med Corps, Command Hosp EC, Kolkata, India
来源：
EUROPEAN RESPIRATORY JOURNAL | 2023年 / 62卷
关键词：
D O I：
10.1183/13993003.congress-2023.PA3303
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 14 条
  • [1] SUCCESSFUL MANAGEMENT OF EOSINOPHILIC MYOCARDITIS IN A PATIENT WITH IDIOPATHIC HYPEREOSINOPHILIC SYNDROME WITH ANTI-IL-5 THERAPY
    Lopez, J.
    Canha, C.
    Cuervo-Pardo, L.
    Matar, R.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 127 (05) : S100 - S100
  • [2] Anti-IL-5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of idiopathic hypereosinophilic syndrome (HES)
    Rondoni, M.
    Paolini, S.
    Ottaviani, E.
    Piccaluga, P. P.
    Papayannidis, C.
    Giannoulia, F.
    De Rosa, F.
    Laterza, C.
    Cilloni, D.
    Baccarani, M.
    Martinelli, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 26 - 27
  • [3] Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions
    Aasha Harish
    Stanley A. Schwartz
    Clinical Reviews in Allergy & Immunology, 2020, 59 : 231 - 247
  • [4] Anti-IL-5 therapy (Mepolizumab) in hypereosinophilic syndromes and eosinophilic esophagitis: Cytokine secretion and decreased peripheral blood eosinophilia
    Stein, ML
    Villanueva, JM
    Jameson, SC
    Buckmeier, B
    Filipovich, AH
    Collins, MH
    Yamada, Y
    Assa'ad, AH
    Rothenberg, ME
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) : S58 - S58
  • [5] Case report: Successful use of mepolizumab for immune checkpoint inhibitors-induced hypereosinophilic syndrome in two patients with solid malignancies
    Lazzari, Chiara
    Yacoub, Mona Rita
    Campochiaro, Corrado
    Bulotta, Alessandra
    Palumbo, Diego
    Ogliari, Francesca Rita
    Dagna, Lorenzo
    Marchesi, Silvia
    Ponzoni, Maurilio
    Gregorc, Vanesa
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [6] Hypereosinophilic syndrome with central nervous system involvement treated with anti-IL-5 therapy
    Jonakowski, M.
    Kuprys-Lipinska, I.
    Lacwik, P.
    Stasiolek, M.
    Matysiak, M.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 51
  • [7] Correction to: Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions
    Aasha Harish
    Stanley A. Schwartz
    Clinical Reviews in Allergy & Immunology, 2020, 59 : 273 - 273
  • [8] USE OF ANTI-IL-5 (MEPOLIZUMAB) AS RESCUE THERAPY FOR STATUS ASTHMATICUS REQUIRING VENOVENOUS EXTRACORPOREAL MEMBRANE OXYGENATION
    Kiani, Ahmed
    Siddique, Daanish
    Sheikh, Adil
    CHEST, 2021, 160 (04) : 1768A - 1768A
  • [9] Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions (vol 17, pg 354, 2020)
    Harish, Aasha
    Schwartz, Stanley A.
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2020, 59 (02) : 273 - 273
  • [10] Baseline demographics and disease characteristics of patients with hypereosinophilic syndrome in a placebo-controlled trial evaluating the steroid-sparing effects of the Anti-IL-5 monoclonal antibody, mepolizumab.
    Gleich, Gerald J.
    Schwartz, Lawrence B.
    Busse, William W.
    Huss-Marp, Johannes
    Walsh, Scott R.
    BLOOD, 2006, 108 (11) : 311B - 311B
12